It is Time to “Overweight” Eidos Therapeutics (EIDX), JPMorgan Says. Stock May Be Worth $36.0

July 16, 2018 - By Megan Stone

Why Has JPMorgan Given Eidos Therapeutics (EIDX) a $36.0 Price Target

JPMorgan published in a recent note that it initiated coverage on Eidos Therapeutics (EIDX) stock, with “Overweight” rating and a $36.0 price target.

The stock increased 5.78% or $1.2 during the last trading session, reaching $21.97. About 112,693 shares traded. Eidos Therapeutics, Inc. (EIDX) has 0.00% since July 16, 2017 and is . It has underperformed by 12.57% the S&P500.

Eidos Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on developing drugs to treat diseases caused by transthyretin amyloidosis (ATTR). The company has market cap of $807.42 million. It is developing AG10, an orally-administered small molecule designed to stabilize tetrameric TTR, thereby halting at its outset the series of molecular events that give rise to ATTR. It currently has negative earnings. The firm was incorporated in 2013 and is headquartered in San Francisco, California.

More notable recent Eidos Therapeutics, Inc. (NASDAQ:EIDX) news were published by: which released: “IPO News This Week: A Record 12 IPOs Coming to Market” on June 24, 2018, also with their article: “8 Biotech Stocks With IPOs This Week” published on June 20, 2018, published: “Premarket analyst action – healthcare” on July 16, 2018. More interesting news about Eidos Therapeutics, Inc. (NASDAQ:EIDX) were released by: and their article: “Eidos Therapeutics Inc (EIDX) CEO Neil Kumar Bought $17 million of Shares” published on June 22, 2018 as well as‘s news article titled: “38 Stocks Moving In Wednesday’s Mid-Day Session” with publication date: June 20, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.